Please assess the completion status of the following clinical trial:

Trial Title: A Study of Pegasys (Peginterferon Alfa-2a) Added to Nucleos(t)Ide Analogue Treatment in Participants With HBeAg-Negative Chronic Hepatitis B Genotype D Showing Stable Hepatitis B Virus (HBV) Deoxyribonucleic Acid (DNA) Suppression

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Adult participants, 18 - 65 years of age~* Chronic hepatitis B~* Negative for HBeAg~* On monotherapy with any nucleos(t)ide analogue (NA) but telbivudine at enrolment, and HBV DNA persistently below 20 IU/ml for at least 12 months~* HBsAg \>100 IU/ml at the beginning of the Lead-in phase, confirmed before addition of Pegasys~* Showing a steady HBsAg kinetic (HBsAg decrease \<0.5 log10 IU/ml from Week -12 to start of the Add-on phase)~* Negative pregnancy test for women of childbearing potential~* Women of childbearing potential and fertile males with female partners of childbearing potential must be using reliable contraception during and for 3 months after the Add-on phase~Exclusion Criteria:~* Coinfection with Hepatitis A virus (HAV), Hepatitis C virus (HCV), Hepatitis D virus (HDV), Human Immunodeficiency virus (HIV)~* Evidence of decompensated liver disease (Child-Pugh \>/=6)~* History or other evidence of a medical condition associated with chronic liver disease (e.g. hemochromatosis, autoimmune hepatitis, alcoholic liver disease, toxin exposure)~* Known hypersensitivity to peginterferon alfa-2a~* Pregnant of breastfeeding women~* Evidence of alcohol and/or drug abuse~* History of severe psychiatric disease, especially depression~* History of immunologically mediated disease~* History or evidence of bleeding from esophageal varices or other conditions consistent with decompensated liver disease~* History or evidence of severe pulmonary disease associated with functional limitations~* History of severe cardiac disease~* History of severe seizure disorder or current anticonvulsant use~* Evidence of an active or suspected cancer or a history of malignancy (other than basocellular carcinoma or in situ cervical carcinoma) within 5 years prior to study entry~* History of having received any systemic anti-neoplastic (including radiation) or immunomodulatory (including systemic corticosteroids) treatment \</= 6 months prior to the first dose or the expectation that such a treatment will be needed at any time during the study~* History or other evidence of severe retinopathy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Pegylated Interferon (Peginterferon) Alfa-2a (Type: EXPERIMENTAL): Participants receiving nucleos(t)ide analogues (NA) therapy with Hepatitis B surface Antigen (HBsAg) decline less than \<0.5 log 10 international unit/milliliter (IU/ml) at baseline received peginterferon alfa-2a 180 microgram (mcg), subcutaneously (SC) once weekly for 48 weeks along with their NA therapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).